MedTrace Logo

Primary Prevention ICD French Registry

NCT01992458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5576

Last updated 2013-11-25

No results posted yet for this study

Summary

The indication of implantable cardioverter defibrillator (ICD) therapy for primary prevention of sudden cardiac death has been introduced later in France than in other parts of the World. Overall, we aimed to assess the risk-benefit ratio of this strategy over a 10 year period.

Conditions

  • Evaluation of Primary Prevention ICD in Real Life

Sponsors & Collaborators

  • Clinique Pasteur Toulouse

    collaborator OTHER

  • European Georges Pompidou Hospital

    collaborator OTHER

  • University Hospital, Grenoble

    collaborator OTHER

  • University Hospital, Bordeaux

    collaborator OTHER

  • University Hospital, Lille

    collaborator OTHER

  • University Hospital, Marseille

    collaborator OTHER

  • Centre Cardiologique du Nord, St Denis

    collaborator UNKNOWN

  • Nouvelles Cliniques Nantaises, Nantes

    collaborator UNKNOWN

  • Hopital Antoine Beclere, Clamart

    collaborator UNKNOWN

  • Rennes University Hospital

    collaborator OTHER

  • Central Hospital, Nancy, France

    collaborator OTHER

  • University Hospital, Tours

    collaborator OTHER

  • Clinique Pasteur

    lead OTHER

Principal Investigators

  • Serge Boveda, MD · Clinique Pasteur

  • Eloi Marijon, MD · Hopital européen Georges Pompidou

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01992458 on ClinicalTrials.gov